🏆 Which companies in the healthcare industry are expected to experience significant revenue growth and have a strong balance sheet?

**🏁 Key Takeaway** Among U.S.-listed healthcare names, the screen below isolates companies posting *at least* 20 % year-over-year revenue growth **and** sporting solid balance-sheet strength (Debt-to-Equity ≤ 0.5 and Current Ratio > 1). From 549 initial hits, only 36 pass the stricter solvency filter; the table highlights the dozen fastest growers. | Rank | Ticker | Company | Rev-Growth YoY | Debt/Equity | Current Ratio | Market Cap | |---|---|---|---|---|---|---| | 1 | GERN | Geron | **5,459 %** | 0.46 | 7.87 | $0.84 B | | 2 | LXRX | Lexicon Pharmaceuticals | 1,653 % | 0.43 | 4.16 | $0.44 B | | 3 | MDGL | Madrigal Pharmaceuticals | 1,354 % | 0.17 | 5.11 | $9.82 B | | 4 | ZTEK | Zentek | 947 % | 0.03 | 2.06 | $0.10 B | | 5 | ENSC | Ensysce Biosciences | 654 % | 0.14 | 2.10 | $0.01 B | | 6 | NUVB | Nuvation Bio | 237 % | 0.14 | 9.39 | $1.09 B | | 7 | ATAI | ATAI Life Sciences | 163 % | 0.04 | 4.02 | $1.01 B | | 8 | XAIR | Beyond Air | 158 % | 0.38 | 5.76 | $0.01 B | | 9 | TARS | Tarsus Pharmaceuticals | 152 % | 0.22 | 5.26 | $2.28 B | | 10 | SXTP | 60 Degrees Pharma | 145 % | 0.07 | 2.27 | $0.006 B | | 11 | CYTK | Cytokinetics | 26,715 %* | –0.02 | 6.76 | $5.90 B | | 12 | BBIO | BridgeBio Pharma | 5,000 %* | –0.01 | 5.19 | $10.20 B | \*Large percentage jumps often reflect a low prior-year base; dig into absolute revenue dollars before committing capital. Data source: Ainvest FinScreener, 18 Sep 2025 --- ### Why These Metrics Matter 🩺 1. **Revenue Growth** – Indicates product adoption or clinical milestone payments; rapid growth can precede valuation re-rating. 2. **Debt-to-Equity ≤ 0.5** – Limits interest-burden risk; several names even show *negative* ratios (net cash positions). 3. **Current Ratio > 1** – Signifies ample short-term liquidity to fund R&D pipelines without immediate dilution. ### How to Use the List • **Triaging the Pack:** • Mid-caps (e.g., MDGL, BBIO) combine robust pipelines with institutional sponsorship—safer but less explosive. • Micro-caps (e.g., ENSC, SXTP) can move 30 – 50 % on a single data read-out—rewarding yet volatile. • **Due-Diligence Checklist:** 1. Upcoming clinical catalysts (Phase-2/3 read-outs, FDA decisions). 2. Cash runway vs. burn rate—ensure at least 12-18 months. 3. Insider ownership and recent secondary offerings. • **Risk Framing:** Even with pristine balance sheets, biotech cash flows are binary. Size positions accordingly and consider pairing with large-cap healthcare for ballast. --- ### Bottom Line 🚀 If you’re hunting for healthcare names capable of **sustained high revenue growth *and* financial resilience**, the companies above represent the current best blend of both. Focus your follow-up research on pipeline quality and near-term catalysts—the fundamental tailwinds are already in place. --- Quick gut-check: Which matters more to you when picking from this list—upcoming clinical catalysts or valuation multiples? 🤔 : Screener universe and raw metrics. : Filtered subset (36 names) meeting the stricter balance-sheet criteria.